TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21406077

Group type: EXPERIMENTAL
Intervention: HIV-1 plasma RNA in female HIV-1 infected partners
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: CD4 count in female HIV-1 infected partners
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Circumcision in HIV-1 uninfected male partners
Number of subjects: 3354
Study: 21406078

Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 26
Study: 21406109

Group type: EXPERIMENTAL
Intervention: 60 mg of standardized Ginkgo biloba two times per day for 12 weeks
Number of subjects: 12
Study: 21406512

Group type: EXPERIMENTAL
Intervention: Antibiotic prescription for patients producing discoloured sputum
Number of subjects: 3402

Group type: COMPARATOR
Intervention: Antibiotic prescription for patients producing clear/white sputum
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for patients producing yellow sputum
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for patients producing green sputum
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for patients feeling unwell
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for patients producing discoloured sputum and feeling unwell
Number of subjects: 3402
Study: 21406610

Group type: EXPERIMENTAL
Intervention: Saliva-derived biomarkers and periodontal pathogens analysis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low biofilm and biomarker levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cluster membership based on salivary biomarkers and biofilm pathogens
Number of subjects: 100
Study: 21407181

Group type: EXPERIMENTAL
Intervention: miR-15b
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: miR-21
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: miR-203
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: miR-486-5p
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: miR-let-7a
Number of subjects: 22
Study: 21408154

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (10 supervised 30-min treadmill sessions over 2 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise
Number of subjects: 12
Study: 21410411

Group type: EXPERIMENTAL
Intervention: Treatment for hepatitis B virus-associated membranous nephritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21410954

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) provided by community health workers (CHWs) for unsupervised treatment at home
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 244
Study: 21410960

Group type: EXPERIMENTAL
Intervention: Escitalopram up to 50 mg
Number of subjects: 60
Study: 21410972

Group type: EXPERIMENTAL
Intervention: CXCL12 expression in epithelial tumor cells
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: CXCL12 expression levels
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: CXCL12 expression impact on survival
Number of subjects: 183
Study: 21411559

Group type: EXPERIMENTAL
Intervention: Thyroid antibody positive (n=245)
Number of subjects: 3593

Group type: COMPARATOR
Intervention: Thyroid antibody negative (n=3348)
Number of subjects: 3593
Study: 21411618

Group type: EXPERIMENTAL
Intervention: Low-choline diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 72

Group type: COMPARATOR
Intervention: PEMT polymorphism rs12325817
Number of subjects: 72

Group type: COMPARATOR
Intervention: Human liver samples
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ratio of DHA-PtdCho to PtdCho in plasma
Number of subjects: 72
Study: 21412372

Group type: EXPERIMENTAL
Intervention: Immunoassay testing (index test)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: LC/MS/MS (reference test)
Number of subjects: 1000
Study: 21414193

Group type: EXPERIMENTAL
Intervention: Zibotentan 10 mg (single oral dose)
Number of subjects: 80
Study: 21414495

Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg at week 0, then 40 mg every other week from week 1)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Adalimumab (for patients previously on etanercept)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Adalimumab (for patients previously on MTX)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Adalimumab (for patients previously on NB-UVB)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 152
Study: 21414634

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Self-Monitored Blood Glucose (SMBG)
Number of subjects: 25
Study: 21414654

Group type: EXPERIMENTAL
Intervention: Enzastaurin
Number of subjects: 27
Study: 21415059

Group type: EXPERIMENTAL
Intervention: mfPERG (multifocal transient pattern electroretinography)
Number of subjects: 23
Study: 21415076

Group type: EXPERIMENTAL
Intervention: Layer-specific myocardial deformation analysis (endocardial, mid-myocardial, epicardial strain)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Endocardial circumferential strain
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Hyperenhancement analysis by ceMRI
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Total wall thickness strain
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Hyperenhancement by ceMRI
Number of subjects: 132
Study: 21415315

Group type: EXPERIMENTAL
Intervention: Home short daily hemodialysis (SDHD) 6 times/week
Number of subjects: 235
Study: 21415456

Group type: EXPERIMENTAL
Intervention: Lower SES African American children
Number of subjects: 272
Study: 21415776

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² (first five patients 60 mg/m²) and pemetrexed 500 mg/m² every 21 days for three cycles with chest radiotherapy to 66 Gy, followed by docetaxel 75 mg/m² every 21 days for three cycles.
Number of subjects: 28
Study: 21416508

Group type: EXPERIMENTAL
Intervention: Proxy-based assessment
Number of subjects: 7479

Group type: COMPARATOR
Intervention: Clinic-based assessment
Number of subjects: 7479
Study: 21418581

Group type: EXPERIMENTAL
Intervention: Global clinical evaluations and Brøset Violence Checklist (BVC) at admittance
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Use of segregation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Actuarial data
Number of subjects: 118
Study: 21419408

Group type: EXPERIMENTAL
Intervention: SpyGlass system
Number of subjects: 75
Study: 21419775

Group type: EXPERIMENTAL
Intervention: 1 dose of AS03- or MF59-adjuvanted vaccines in immunocompetent children
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 2 doses of AS03- or MF59-adjuvanted vaccines in immunocompromised children
Number of subjects: 126

Group type: COMPARATOR
Intervention: Convalescent children (natural infection)
Number of subjects: 126
Study: 21421838

Group type: EXPERIMENTAL
Intervention: Recipients after allogeneic stem cell transplantation (SCT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Donors at transplant
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TCR repertoire analysis
Number of subjects: 21
Study: 21421840

Group type: EXPERIMENTAL
Intervention: Clonal peripheral B cells in HCV(+)MC(+) patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD27(+)CD21(low) B-cell subset
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD27(+)CD21(high) B-cell subset
Number of subjects: 0
Study: 21422405

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 0
Study: 21422474

Group type: EXPERIMENTAL
Intervention: HIV-specific CD8+ T-cell clones derived from HIV-reactive CD28+CD8+ T-cell lines
Number of subjects: 7
Study: 21425150

Group type: EXPERIMENTAL
Intervention: Clofarabine (CLO) 4 mg/m², administered as a 1-hour intravenous infusion daily for 5 days every 28 days (maximum 6 cycles)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clofarabine (CLO) in rituximab-refractory patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clofarabine (CLO)
Number of subjects: 31
Study: 21425247

Group type: EXPERIMENTAL
Intervention: Novartis MF59-adjuvanted H1N1v monovalent influenza vaccine
Number of subjects: 119

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: RA and PsA patients
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: DAS28, BASDAI, and SLEDAI
Number of subjects: 119
Study: 21426510

Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment with secondary hyperparathyroidism management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 21426511

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) treatment, flexible daily dosage of 750-4500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) treatment
Number of subjects: 0
Study: 21426546

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 219
Study: 21426560

Group type: EXPERIMENTAL
Intervention: Urinary proteomic analyses using MALDI-TOF MS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched non-delirium patients after cardiac surgery
Number of subjects: 10
Study: 21427395

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 5507

Group type: EXPERIMENTAL
Intervention: Azithromycin (compared within households)
Number of subjects: 5507
Study: 21429209

Group type: EXPERIMENTAL
Intervention: Postprandial changes in cardiac output (CO)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Postprandial changes in heart rate (HR)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Postprandial changes in stroke volume (SV)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging systolic longitudinal ventricular velocity of the septum (S's)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging systolic longitudinal ventricular velocity of the lateral wall (S'l)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging early diastolic longitudinal ventricular velocity of the lateral wall (E'l)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging late diastolic longitudinal ventricular velocity of the septum (A's)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging late diastolic longitudinal ventricular velocity of the lateral wall (A'l)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gastric emptying rate (GER)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glucose and insulin concentrations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Satiety
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 23
Study: 21429580

Group type: EXPERIMENTAL
Intervention: Heart failure patients (HF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study: 21431345

Group type: EXPERIMENTAL
Intervention: Gefitinib and pegylated-IFNα (PEG-IFNα)
Number of subjects: 21
Study: 21432592

Group type: EXPERIMENTAL
Intervention: Atomoxetine (target dose 0.5-1.2 mg/kg/day)
Number of subjects: 421
Study: 21433272

Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/hr infusion)
Number of subjects: 110
Study: 21435246

Group type: EXPERIMENTAL
Intervention: Internet-based lifestyle intervention program
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Facilitators for lifestyle change
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Barriers to lifestyle change
Number of subjects: 25
Study: 21435513

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 15147
Study: 21436300

Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Asymptomatic PAD participants
Number of subjects: 427
Study: 21436454

Group type: EXPERIMENTAL
Intervention: CD40 agonist antibody combined with gemcitabine chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD40 agonist antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD40-activated macrophages
Number of subjects: 0
Study: 21436711

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment
Number of subjects: 16
Study: 21436758

Group type: EXPERIMENTAL
Intervention: aEEG assessment within the first week
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: aEEG assessment within the second week
Number of subjects: 143

Group type: COMPARATOR
Intervention: Cerebral ultrasound assessment within the first week
Number of subjects: 143

Group type: COMPARATOR
Intervention: Cerebral ultrasound assessment within the second week
Number of subjects: 143
Study: 21437515

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) patients
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 261
Study: 21437851

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound elastography (EUS elastography)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Qualitative analysis by two expert doctors
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Intra-observer variability analysis
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Average-hue histogram analysis of EUS elastography videos
Number of subjects: 258
Study: 21439051

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 21439671

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 3224
Study: 21440300

Group type: EXPERIMENTAL
Intervention: Prenatal medical food
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard PNVs
Number of subjects: 112
Study: 21440503

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg/week and rituximab 375 mg/m(2) per week for 4 weeks, then rituximab every other 28-day cycle for a total of 12 cycles.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Temsirolimus and rituximab in rituximab-sensitive patients.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Temsirolimus and rituximab in rituximab-refractory patients.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events in rituximab-sensitive patients.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events in rituximab-refractory patients.
Number of subjects: 71
Study: 21440865

Group type: EXPERIMENTAL
Intervention: P×T (pressure-based hemodynamic factor) in patients with HFRE
Number of subjects: 274

Group type: COMPARATOR
Intervention: P×T (pressure-based hemodynamic factor) in patients without HFRE
Number of subjects: 274
Study: 21441100

Group type: EXPERIMENTAL
Intervention: Web-based Guide to Health (WB-GTH) intervention
Number of subjects: 963
Study: 21441399

Group type: EXPERIMENTAL
Intervention: Single urinary albumin excretion (UAE) measurement
Number of subjects: 4062

Group type: EXPERIMENTAL
Intervention: Albumin excretion rate (AER) measurement
Number of subjects: 4062

Group type: EXPERIMENTAL
Intervention: Immunoturbidimetry
Number of subjects: 4062

Group type: EXPERIMENTAL
Intervention: Multiple UAE measurements (geometric mean)
Number of subjects: 4062
Study: 21443558

Group type: EXPERIMENTAL
Intervention: Clinical periodontal examination and assessment of sperm quality according to WHO criteria.
Number of subjects: 75
Study: 21443790

Group type: EXPERIMENTAL
Intervention: Blood-based gene expression algorithm
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Microarray analysis of RNA samples
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: RT-PCR analysis of CAD classifier genes
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Microarray cohort analysis
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Algorithm development using RT-PCR analysis of 113 genes
Number of subjects: 640
Study: 21443962

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 2635
Study: 21444917

Group type: EXPERIMENTAL
Intervention: Prephase chemotherapy followed by 3 courses of chemotherapy (for 6 patients with complete resection)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prephase chemotherapy followed by 6 courses of chemotherapy (for 30 patients without complete resection)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stage I patients (incomplete resection)
Number of subjects: 36
Study: 21445332

Group type: EXPERIMENTAL
Intervention: Complement regulatory proteins mutations (MCP, CFI, CFH)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Risk variants in MCP or CFI
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Novel mutation in MCP
Number of subjects: 250

Group type: COMPARATOR
Intervention: Hypomorphic variants of MCP and CFI
Number of subjects: 250
Study: 21446778

Group type: COMPARATOR
Intervention: Edoxaban tosylate
Number of subjects: 21500
Study: 21446779

Group type: EXPERIMENTAL
Intervention: Varespladib
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 6500
Study: 21447161

Group type: EXPERIMENTAL
Intervention: 12-lead ECG and advance emergency department (ED) notification
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3-lead ECG monitoring and alert to dispatch prior to hospital arrival
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bypass to PCI centre (with or without prehospital strategies)
Number of subjects: 0
Study: 21447197

Group type: EXPERIMENTAL
Intervention: Modified anteriolateral bent knee portal
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard lateral midpatellar portal
Number of subjects: 83
Study: 21447719

Group type: EXPERIMENTAL
Intervention: AS1409 at 15 μg/kg weekly
Number of subjects: 13
Study: 21447834

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 559
Study: 21447948

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 189
Study: 21448080

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: h-FABP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: cystatin C
Number of subjects: 102
Study: 21448128

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) measured by accelerometers
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Vigorous Physical Activity
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Baseline motor skills, aerobic fitness or %body fat
Number of subjects: 217
Study: 21448355

Group type: EXPERIMENTAL
Intervention: NSAID consumption
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-users of NSAIDs
Number of subjects: 54
Study: 21448937

Group type: EXPERIMENTAL
Intervention: Diet Energy Density Score (DEDS)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diet Variety Score (DVS)
Number of subjects: 19
Study: 21450159

Group type: EXPERIMENTAL
Intervention: Ketamine, acute course, dosage and duration not specified
Number of subjects: 0
Study: 21450208

Group type: EXPERIMENTAL
Intervention: First tertile of PWV
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Second tertile of PWV
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Third tertile of PWV
Number of subjects: 873
Study: 21450573

Group type: EXPERIMENTAL
Intervention: Carvedilol at maximal tolerated dose
Number of subjects: 30
Study: 21450900

Group type: EXPERIMENTAL
Intervention: Imatinib (IM) frontline treatment
Number of subjects: 559
Study: 21450987

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 956

Group type: COMPARATOR
Intervention: Exenatide 10 μg
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Switching from exenatide to liraglutide
Number of subjects: 956
Study: 21454450

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immunosuppressive agents, rituximab, autologous cytotoxic T cells, cytotoxic chemotherapy
Number of subjects: 0
Study: 21454794

Group type: EXPERIMENTAL
Intervention: Mitochondrial tRNA(Ile) 4263A>G mutation
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Mitochondrial dysfunction due to 4263A>G mutation
Number of subjects: 106
Study: 21454813

Group type: EXPERIMENTAL
Intervention: Intravenous dantrolene 1.25 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous dantrolene 2.5 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 21455550

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg BIW for 12 weeks followed by 50 mg OW for 12 weeks
Number of subjects: 10
Study: 21455908

Group type: EXPERIMENTAL
Intervention: Emergency tourniquet use in prehospital settings (671 limbs, 70%)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Emergency tourniquet use in hospital settings (104 limbs, 11%)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Emergency tourniquet use in both prehospital and hospital settings (169 limbs, 18%)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Situations indicating tourniquet use (bleeding from multiple sites other than limbs, hospital mass casualty situations)
Number of subjects: 728
Study: 21457513

Group type: EXPERIMENTAL
Intervention: sVEGFR-1
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: uPA
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: VEGF
Number of subjects: 101
Study: 21458098

Group type: EXPERIMENTAL
Intervention: Adiponectin to homeostasis model assessment of insulin resistance (A/H ratio)
Number of subjects: 0
Study: 21458303

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT)
Number of subjects: 96
Study: 21458777

Group type: EXPERIMENTAL
Intervention: Abbreviated Late-Life Function and Disability Instrument (LL-FDI)
Number of subjects: 179
Study: 21458812

Group type: EXPERIMENTAL
Intervention: Community-based intervention in rural Nepal (exact details of intervention not specified)
Number of subjects: 24531

Group type: COMPARATOR
Intervention: Not applicable (observational data)
Number of subjects: 24531
Study: 21458906

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 21459588

Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy (BNCT) combined with fractionated X-ray irradiation and temozolomide.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Boron neutron capture therapy (BNCT)
Number of subjects: 0